The event is over. A replay and transcript will be available shortly.
About Presenters
Dr. Dima Dim Dim, PhD
Dima Dim Dim is a distinguished serial entrepreneur and full time investor, dedicating his expertise and capital to areas of business that are overlooked and underrepresented. This was his basis for launching PropThink: proprietary research was only accessible to larger investors able to afford paying for it. PropThink levels the playing field by giving all investors equal access through the distribution of proprietary research. Dmytry is a value investor with a slight preference towards shorting companies that have unsustainable models and disconnected valuations. In his free time he enjoys reading investigative journalism, watching hard-hitting documentaries and challenging himself with Sudoku puzzles.
About Company
Orgenesis (ORGS) specializes in cell therapy manufacturing and development.
The Company’s manufacturing arm, MaSTherCell, provides Contract Development and Manufacturing (CDMO) services to leading biotech companies, research institutions and hospitals involved in drug devemlopment. Clients include CRISPR Therapeutics (CRSP) and AdaptImmune (ADAP).
Whereas their technology platform focuses on developing a process that uses a diabetic person’s own liver cells to produce insulin, with the goal of curing insulin dependent diabetes. Orgenesis uses the cash flows from their manufacturing business to fund the development of their technology platform.
Investor Questions
| User | Question |
|---|
Legal Disclaimer: PropThink Digital Conferences are organized and marketed by PropThink LLC ("PropThink" or "we") with the aim of connecting subject matter experts with investors. This Digital Conference is sponsored by Bellus Health Inc. (the "Company") who has agreed to pay fifteen thousand dollars for PropThink to organize, market and host a Digital Conference featuring the Company. PropThink is not a registered investment advisor in any jurisdiction. We do not publish investment advice and remind readers that investing involves considerable risk. PropThink urges all readers to carefully review the Company's regulatory filings and consult with an investment professional before making any investment decisions. Please read our full disclaimer at http://propthink.com/disclaimer
